by Sowmya Viswanathan | Mar 12, 2018
Dr. Sheng Lin-Gibson is the Chief of Biosystems and Biomaterials Division at the U.S. National Institute of Standards and Technology (NIST) and directs its Regenerative Medicine Programs. She serves as the Convenor of ISO/TC 276: Biotechnology Working Group...
by Stacey Johnson | Feb 2, 2018
Cell and Gene Therapy World, or “Phacilitate” as delegates like to refer to it, happened last week in Miami, Florida (January 22-25). The conference, with 1,500 in attendance, brings together industry professionals from more than 30 countries. The event...
by Sara M. Nolte | Jan 15, 2018
With the start of a new year, I like to take a moment to think about what things in cancer research got me really excited the previous year. Beyond a doubt, that thing for me in 2017 was the first (and second!) FDA approval of a CAR T-cell (chimeric antigen receptor...
by Sowmya Viswanathan | Jan 8, 2018
In this month’s blog on addressing specific bioprocess and bioanalytical challenges to develop Cell and Gene Therapies (CGTs), we hear from Dr. Nick Timmins on quantifying performance of CGTs using cell yield, and some of the methods to measure it, as a metric...
by Sowmya Viswanathan | Nov 30, 2017
The recent FDA approvals of Kymriah™ for the treatment of children and young adults with B-cell Acute Lymphoblastic Leukemia, and Yescarta™ to treat adults with certain types of non-Hodgkin lymphoma, and the unanimous endorsement by an FDA advisory committee of a gene...
by Samantha Yammine | Nov 23, 2017
With the extensive exploitation of regenerative medicine through the marketing and selling of unapproved stem cell “therapies” online, it was refreshing to hear an update about clinical trials for a legitimate stem cell therapy at the Till & McCulloch Meetings...
Comments